Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevuparin - Modus Therapeutics

Next Previous
X
Search
Drug Profile

Sevuparin - Modus Therapeutics

Alternative Names: DF-02; Low anticoagulant heparin - Modus Therapeutics

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dilafor
  • Developer Arabian Gulf University; Imperial College of Science, Technology and Medicine; Mahidol Oxford Tropical Medicine Research Unit; Modus Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antianaemics; Anticoagulants; Antimalarials; Antithrombotics; Heparins; Low molecular weight heparins; Polysaccharides; Urologics
  • Mechanism of Action Cell adhesion molecule inhibitors; E-selectin inhibitors; Fibronectin receptor antagonists; L-selectin inhibitors; P selectin inhibitors; Thrombospondin antagonists; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vaso-occlusive crisis
  • Phase I Sepsis
  • Preclinical Kidney disorders

Most Recent Events

  • 11 Dec 2023 Pharmacokinetic data from the preclinical studies in Anemia was released by Modus Therapeutics
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Anemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 02 Nov 2023 Pharmacodynamics data from preclinical trials in Kidney disorders released by Modus Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top